BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 25704226)

  • 1. Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma.
    Deipolyi AR; Oklu R; Al-Ansari S; Zhu AX; Goyal L; Ganguli S
    J Vasc Interv Radiol; 2015 Apr; 26(4):516-22. PubMed ID: 25704226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
    Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS
    J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
    Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
    J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-center comparison of three chemoembolization regimens for hepatocellular carcinoma.
    Petruzzi NJ; Frangos AJ; Fenkel JM; Herrine SK; Hann HW; Rossi S; Rosato EL; Eschelman DJ; Gonsalves CF; Brown DB
    J Vasc Interv Radiol; 2013 Feb; 24(2):266-73. PubMed ID: 23261143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma.
    Vadot L; Boulin M; Guiu B; Aho LS; Vourc'h M; Musat A; Hillon P; Lepage C; Guignard MH; Fagnoni P
    J Clin Pharm Ther; 2015 Feb; 40(1):83-90. PubMed ID: 25413186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transarterial hepatic chemoembolization with 70-150 µm drug-eluting beads: assessment of clinical safety and liver toxicity profile.
    Odisio BC; Ashton A; Yan Y; Wei W; Kaseb A; Wallace MJ; Vauthey JN; Gupta S; Tam AL
    J Vasc Interv Radiol; 2015 Jul; 26(7):965-71. PubMed ID: 25979305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of drug-eluting bead chemoembolization for hepatocellular carcinoma: comparison of small-versus medium-size particles.
    Padia SA; Shivaram G; Bastawrous S; Bhargava P; Vo NJ; Vaidya S; Valji K; Harris WP; Hippe DS; Kogut MJ
    J Vasc Interv Radiol; 2013 Mar; 24(3):301-6. PubMed ID: 23380737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conventional versus Drug-Eluting Bead Transarterial Chemoembolization for Neuroendocrine Tumor Liver Metastases.
    Makary MS; Kapke J; Yildiz V; Pan X; Dowell JD
    J Vasc Interv Radiol; 2016 Sep; 27(9):1298-1304. PubMed ID: 27499157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
    Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
    AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superselective Chemoembolization of HCC: Comparison of Short-term Safety and Efficacy between Drug-eluting LC Beads, QuadraSpheres, and Conventional Ethiodized Oil Emulsion.
    Duan F; Wang EQ; Lam MG; Abdelmaksoud MH; Louie JD; Hwang GL; Kothary N; Kuo WT; Hofmann LV; Sze DY
    Radiology; 2016 Feb; 278(2):612-21. PubMed ID: 26334787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
    Niessen C; Unterpaintner E; Goessmann H; Schlitt HJ; Mueller-Schilling M; Wohlgemuth WA; Stroszczynski C; Wiggermann P
    J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idarubicin-loaded ONCOZENE drug-eluting embolic agents for chemoembolization of hepatocellular carcinoma: in vitro loading and release and in vivo pharmacokinetics.
    Guiu B; Schmitt A; Reinhardt S; Fohlen A; Pohl T; Wendremaire M; Denys A; Blümmel J; Boulin M
    J Vasc Interv Radiol; 2015 Feb; 26(2):262-70. PubMed ID: 25311967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future.
    Woo HY; Heo J
    Clin Mol Hepatol; 2015 Dec; 21(4):344-8. PubMed ID: 26770921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning-An Artificial Intelligence Concept.
    Abajian A; Murali N; Savic LJ; Laage-Gaupp FM; Nezami N; Duncan JS; Schlachter T; Lin M; Geschwind JF; Chapiro J
    J Vasc Interv Radiol; 2018 Jun; 29(6):850-857.e1. PubMed ID: 29548875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results.
    de Baere T; Deschamps F; Teriitheau C; Rao P; Conengrapht K; Schlumberger M; Leboulleux S; Baudin E; Hechellhammer L
    J Vasc Interv Radiol; 2008 Jun; 19(6):855-61. PubMed ID: 18503899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
    Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD
    J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and feasibility of same-day discharge of patients with hepatocellular carcinoma treated with transarterial chemoembolization with drug-eluting beads in a liver transplantation program.
    Nasser F; Cavalcante RN; Galastri FL; de Rezende MB; Felga GG; Travassos FB; De Fina B; Affonso BB
    J Vasc Interv Radiol; 2014 Jul; 25(7):1012-7. PubMed ID: 24704346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the relationship between hepatocellular carcinoma location and transarterial chemoembolization efficacy.
    Miki I; Murata S; Uchiyama F; Yasui D; Ueda T; Sugihara F; Saito H; Yamaguchi H; Murakami R; Kawamoto C; Uchida E; Kumita SI
    World J Gastroenterol; 2017 Sep; 23(35):6437-6447. PubMed ID: 29085193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoembolization of hepatocellular carcinoma with HepaSphere 30-60 μm. Safety and efficacy study.
    Malagari K; Pomoni M; Moschouris H; Kelekis A; Charokopakis A; Bouma E; Spyridopoulos T; Chatziioannou A; Sotirchos V; Karampelas T; Tamvakopoulos C; Filippiadis D; Karagiannis E; Marinis A; Koskinas J; Kelekis DA
    Cardiovasc Intervent Radiol; 2014 Feb; 37(1):165-75. PubMed ID: 24263774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
    Pinter M; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Stauber R; Grünberger B; Müller C; Kölblinger C; Peck-Radosavljevic M; Sieghart W
    Radiology; 2012 May; 263(2):590-9. PubMed ID: 22438359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.